August 11, 2022 Synthetic Biologics Reports Second Quarter 2022 Operational Highlights and Financial Results
August 4, 2022 Synthetic Biologics to Host Conference Call and Webcast to Discuss Second Quarter 2022 Operational Highlights and Financial Results
July 29, 2022 Synthetic Biologics Announces $3 Million Private Placement of Convertible Preferred Stock
May 16, 2022 Synthetic Biologics Reports First Quarter 2022 Operational Highlights and Financial Results
May 10, 2022 Synthetic Biologics Reports Positive Safety Data on SYN-020 Intestinal Alkaline Phosphatase Phase 1 Multiple Ascending Dose Clinical Trial
May 9, 2022 Synthetic Biologics to Host Conference Call and Webcast to Discuss First Quarter 2022 Operational Highlights and Financial Results
May 5, 2022 Synthetic Biologics Announces Formation of Scientific Advisory Board to Advance Oncology Pipeline
May 4, 2022 Synthetic Biologics Announces Presentation on VCN-11, a Novel Oncolytic Adenovirus Designed to Evade Neutralizing Antibodies at the Upcoming 25th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
